Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If this is actually being discussed then Aethlon would definitely be involved. IMO
http://www.foxnews.com/politics/interactive/2014/10/28/state-department-memo-on-ebola-policies/
If this is true then someone must a great ebola treatment plan. I've wondered that if the Hemopurifier could be used on the plane ride to the USA the viral load would already be reduced prior to landing, making the virus more manageable upon arrive for hospital treatment.
http://washington.cbslocal.com/2014/10/28/gop-rep-white-house-developing-plans-to-bring-non-american-ebola-patients-to-us-for-treatment/
It will be interesting to hear what Amber Vinson says today during her press conference. She reported being ebola free before Pham. Pham was given Brantly's blood, but I do not know Vinson's treatment. Even after Vinson reported being ebola free she stayed in the hospital for another six or so days, when Pham was immediately released last week.
I'm not sure of what the normal time frame is to contract and then show no signs of ebola, but the nurse, Amber, may have broke an ebola recovery record. That was fast... IMO....This is also just based on third party information...
http://www.nbcdfw.com/news/local/Dallas-Nurse-Amber-Vinson-No-Longer-Has-Ebola-Family-280110332.html
Yes laker5, It's good to see longs still here. I was wondering where everyone went. Like most longs, its great to finally see positive movement and volume. I'm over 5 years long and can't wait to see Aethlon helping to save lives. Hopefully soon we hear great news from Frankfurt.
It's weird to me that Aethlon has received zero TV news coverage. CNN talks about everything including unknown ebola vaccines, but will not cover Aethlon's work. I think that will change this week. Also, Question, do we know exactly what patient was treated by Aethlon? Is it possible that they treated the first patient that is already released and the current still at Frankfurt is the second? Usually, Aethlon is a few weeks ahead of their announcements. Just wondering.
Question, is it confirmed that the current Frankfurt patient was treated by Aethlon? Is it possible that the patient that was released was the first and the current patient is #2? Aethlon is good about being ahead of the news game...
I'm not sure if everyone on this board has seen this response on Aethlon's Facebook page, dated Oct. 2nd, regarding ebola.
"Aethlon Medical We cannot discuss conversations we have had with government agencies. However, I will point out that our Hemopurifier was originally created specifically for these types of events. To augment the benefit of established therapies and to fill the void for the breadth of pathogens that are not effectively addressed with drug or vaccine therapies. In fact, the original authors of Project Bioshield (which launched the industry for bioterror and pandemic countermeasures) had us provide congressional testimony and then marched us around Capital Hill as a means to expand the legislative definition of bioterror and pandemic countermeasure to include a medical device versus the definition being solely limited to a drug or vaccine. With that said, we now have an approved IDE from FDA (after years of effort) that allows us the opportunity to clinically advance our first-in-class technology in the United States. In regards to treating individuals infected with ebola virus, we cannot share details beyond what was previously disclosed on August 6th at this time."
The words "We cannot share details" means to me that there's more and they will share those details at a later date.
Missed the prior post..Sorry, now I can't delete it.
This is interesting. Looks like Aethlon is getting competition?
http://www.washingtonpost.com/news/to-your-health/wp/2014/09/16/from-e-coli-to-ebola-a-device-that-can-filter-deadly-pathogens-out-of-the-body/
Below was taken from the CDC ebola question and answer page. It's amazing that Aethlon is not even mentioned as a possible experimental treatment, even with collected data.
"Are there other companies developing experimental treatments or vaccines?
Two other companies, Tekmira and Biocryst Pharmaceuticals, receive funding from the Department of Defense's Defense Threat Reduction Agency and have therapeutic candidates for Ebola in early development. The Department of Defense is working with a company called Newlink to develop an Ebola vaccine candidate. BioCryst, with NIH support, is working to develop an antiviral drug to treat Ebola virus that is expected to begin Phase 1 testing later this year."
http://www.cdc.gov/vhf/ebola/outbreaks/guinea/qa-experimental-treatments.html?scrlybrkr
I was surprised that JJ is actually responding to posts on his Chairman's blog. This was taken from today's response to a post.
"In regards to overseas opportunities, we will pursue the treatment of certain pathogens if the resulting data can also be utilized to expand our U.S. therapeutic indications through Emergency Use Authorization (EUA) or Humanitarian Use Device (HDE) pathways"
It's been over a month since JJ stated they was talking to the FDA. I wonder, if at all, how long it will take to receive a positive response.
Lets hope a representative from Aethlon is attending the WHO conference.
http://www.ibtimes.com/ebola-outbreak-world-health-organization-officials-meet-second-day-discuss-treatments-1679610
"In a statement from the United Nations, WHO said: “There is intense public interest in, and demand for, anything that offers hope of definitive treatment. A range of unproven interventions-blood products, immune therapies, drugs and vaccines are under different stages of development but none have yet been licensed for standard use.”
I have a hard time believing the FDA is holding back Aethlon as this crisis increases. Within the next month the death rate will be over 2,000. It must be hard to bare knowing you have something that could help, but politics hold you back. If there was ever a time for the Hemopurifier it was a month ago, but its not to late to save lives. Aethlon's slogan is "Save Lives", So let them do it..
http://www.latimes.com/world/africa/la-fg-africa-ebola-20140828-story.html
I'm hoping the safety study delay is based on getting the new September filters over to Africa. By December Aethlon would have plenty of time to make new filters for the FDA study.
JJ says their working on their balance sheet and hopefully uplifting to Nasdaq? Interesting.
http://thestockradio.com/aemd-aethlon-medical-inc-james-a-joyce-chairman-ceo/
This would be a great time for a shareholders letter. In fairness to the shareholders a simple "Our company is not involved in the treatment of the two Americans with Ebola" would suffice. With Aethlon's past experience and prior statements makes most believe there is a high probability that the Hemopurifier would be involved. A simple letter and communication would ease our minds, especially since this is world news.
The way I look at this is ZMapp is putting their eggs all in one basket, and it's not even proven that their drug is changing the outcome of the patients. I think Aethlon would be involved if there were shipments to Africa to control and help multiple patients. Plus, let's hope their using the humopurifier in conjunction with other care. Why not? Work on the immune system and at the same time reduce viral load with the humopurifier. If it's obvious to us, then you know they have already thought about it. IMO
Most of us on this board have talked about the main reason for investing is being able to see this device save lives. I don't know any other time then now to allow the Hemopurifier to do its job. There is a good chance hopefully to save these two people and I will be shocked and upset if they do not use any possible experimental drug or device to do what ever it takes to save them. These two wonderful people sacrificed their lives to help save others and it would only be right to do whatever it takes to do the same for them.
Below was taken from Aethlons "Aethlon Medical Announces Online Access to Infectious Disease and Cancer Therapy Presentation"
"The results of government and non-government collaborative testing programs against category "A" bioterror and pandemic threats, including pandemic influenza, dengue, ebola, pox viruses, and other viral pathogens that remain untreatable with drug or vaccine therapies."
Unless there is something else out there, I sure hope they use what's available and capable of making a difference in their health.
Lets hope they have a dialysis machine and Hemopurifier cartridges on board the plan to start the process early.
http://www.cbsnews.com/news/ebola-crisis-us-racing-to-bring-two-infected-americans-home/
Thanks...That is exactly my point. I apologize if it sounded different, but I thought my point was obvious.
It's not about spreading. There is no reason to bring them home now unless there is a treatment plan. Why spend the money....private plan, manpower, possible exposer, just to die in the US. They could do it a lot cheaper after the fact...IMO..
What I find interesting about that is why bring the virus to the USA if there is no possible cure and take any chance of spreading virus to someone else on US soil. Would think they would keep it completely contained...very interesting.
Someone else dreaming about Aethlon getting involved with the Ebola issue.
http://ireport.cnn.com/docs/DOC-1157208?ref=feeds%2Flatest
We can all relax. We need to stay focused on what we know and not jump to assumptions based on the unknown. Some have seen .27 or higher drop to .6 and lower. We need to stay focused on our objective, which is the same objective as Aethlon. There will be no surprises based on what we know. So, what do we know.....Why would Davita agree to work with Aethlon? what about our government contract, which is probably going great? What about MD Anderson working with Aethlon? ESI and there great advancements? They know more then we do. Do you think this would have happened if there is bad news coming? We all study hard to protect our investment. With that said, we're all good...:) Have a great day tomorrow and enjoy JJ's talk.
Exactly. I would like to know the cancer programs, goals, and established partners.
Tomorrow JJ is supposed to provide a review of the company's cancer programs. I do not recall what cancer programs Aethlon has. I was under the assumption that exosomes were going to take place after the initial IDE trial. So, besides ESI, can someone tell me what cancer programs Aethlon is currently involved in?
They still haven't said how they are paying the $200,000 for trials and they are giving raises? I guess raises are more important then getting your product to market..Confusing...
Did anyone else find it unusual that JJ didn't mention ESI at all in his interview? Seemed weird to me to be talking about the Emerging Immuno-Oncology Market and leave out the number one player, ESI. IMO
I'm sure there is no connection, but I find it interesting that Aethlon announced their agreement with Davita on May 20th and since that date Davita has blossomed from about $67.50 to a high today at about $71.43. I'm no expert, and besides insider trading, there has been no real news for this nice upward movement.
Now today, Davita announces a 5.5 billion dollar loan for this reason, "to refinance its existing credit facilities and the existing $775 million 6.375% senior notes due 2018, as well as for general corporate purposes."
It's nice that Davita is thinking four years ahead to pay off senior notes due in 2018.
Davita's looking good, so now we need news of when they are starting the FDA IDE study. By the way, has anyone heard of where Aethlon is coming up with the $200,000+ for the trial? I missed that part..
https://finance.yahoo.com/news/davita-healthcare-partners-inc-announces-130000554.html
Again, back to my assumptions, but personally I believe there is relevance to little things.
As we know Aethlon has not attempted to update their website for over a year (1 YEAR). For about the last 6 months ESI's and Aethlon's websites have completely contradicted each other. Why, lack of money or time? I feel that a lot is changing and Aethlon is only stalling until ESI's fate is determined. ESI's website would be an easy fix, but Aethlon's, not so easy, and why double your work. Stall, stall, stall...IMO...
I was thinking that a large drug company could possibly acquire ESI, but now I'm wondering if maybe Davita could be interested. Davita recently announced HEP C, HIV testing with Roche's tester, which is completely new and the first for a dialysis company. The new hype will soon be in cancer exosome blood testing. I figure if you are going to get into blood testing why not just go all in, especially since cancer exosome blood testing is right around the corner and you have ESI + patents at your fingertips. We are now seeing the connection between companies, and primarily its about cancer exosomes. Below was taken from ESI's recent announcement, which to me says it all. Either way I'd say we are looking really good.
"Building on our proprietary method to identify, quantitate and characterize brain-derived exosomes, we now have the ability to detect this aggressive cancer early and aid in its treatment," stated ESI Chief Scientific Officer, Dr. Douglas Taylor.
$200,000 seems pretty cheap. I'm sure there will be other expenses, but overall not a bad price for an initial FDA IDE study. Someone must be helping, or they just got a great discounted rate. What I like is that there will be a lot more interest after good trial results, especially with Davita themselves. I'm a little confused because Dr. Fadem seems more interested in the exosome studies then Hep C if you read his recent blog, but I guess it one step at a time.
http://kidneyblogsite.blogspot.com/
I'm thinking the IDE trial should go a lot faster then the India study with the clinic having over 72 dialysis machines (Only need 10) the the high tech molecular diagnostic testing from Roche. I like the underlined sentence below. Also, if I'm not mistaken, didn't Aethlon mention awhile back that they were updating and improving the Hemopurifier?
"This molecular diagnostic testing will allow DaVita Labs to be the first dialysis laboratory in the country to test for Hepatitis C (HCV) virus levels in the blood (viral load) using the COBAS Ampliprep/COBAS TaqMan HCV v.2 test from Roche. This DNA-based technology will enable DaVita Kidney Care to help nephrologists manage patients with chronic HCV in conjunction with clinical and laboratory markers of infection. The test can be used to predict the probability of sustained virologic response (SVR) early during a course of antiviral therapy, and to assess a patient's response to antiviral treatment."
SVR + lower cost = WIN. Aethlon is way behind, but this year would be a great time to move into the Hep C/ Cancer space.
http://www.cnbc.com/id/101697100?__source=yahoo%257cfinance%257cheadline%257cheadline%257cstory&par=yahoo&doc=101697100%257cWhen+the+price+is+wrong:+
"Tests for Double-Stranded DNA Fragments in Exosomes Could Lead to Earlier, Easier Cancer Diagnoses and Targeted Treatments"
http://weill.cornell.edu/news/news/2014/05/tests-for-double-stranded-dna-fragments-in-exosomes-could-lead-to-earlier-easier-cancer-diagnoses-an.html
Not sure, but I'd like a round about figure.
It's just my assumption that it would be a good time for a drug company to announce a partnership with Aethlon.
Davita announced recently that it has implemented molecular diagnostic testing using technology from Roche Diagnostics.
http://finance.yahoo.com/news/davita-labs-uses-roche-technology-100300935.html
Secondly, Aethlon states in their last PR:
"In HCV care, the device is positioned to address drug resistance associated with emerging all-antiviral therapies and also targets to accelerate HCV RNA depletion at the outset of peginterferon+ribavirin (PR) therapy."
With this, Aethlon has announced two recent PR's
"We envisioned the possibility that a medical device could eliminate circulating exosomes and combine to improve the benefit of established cancer therapies without adding drug toxicity."
"In this regard, Aethlon Medical is the only organization referenced based on our extracorporeal device strategy to target the elimination of exosomes from circulation of cancer patients."
In this regard I believe Aethlon is loading up and not just bolstering.
I'm thinking the same thing. I just find it interesting that Aethlon is loading PR at the same time other drug companies are announcing prior to the ASCO. May 30th time frame should be pretty interesting. IMO
Something tells me that Aethlon is loading up and the PR's are not over. I'm expecting two more good PR's by the end of the month. IMO